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ABSTRACT
Introduction: Current pathways for treatment
of partial onset epilepsy are diverse and include
14 new antiepileptic drugs (AEDs) licensed for
use as either monotherapy or adjunctive
therapy. However, the impact of these new
AEDs on the treatment of partial epilepsy has so
far been disappointing and there persists a need
for additional drugs. Recently, perampanel, a
first-in-class AED was licensed as an adjunct for
the management of refractory partial onset
seizures with or without secondary
generalization in patients 12 years and older.
This review highlights the current management
of partial epilepsy and analyses the published
clinical and preclinical data of perampanel to
consider its potential role in the treatment of
partial epilepsy.
Methods: A literature review of Embase,
Medline and PubMed was conducted in April
2013 using the search terms ‘perampanel’ and
‘AMPA receptor antagonist/blocker’.
Publications were included if they discussed
perampanel in the context of preclinical or
clinical epilepsy.
Results: Perampanel acts on the glutamate
pathway. It is a novel highly selective non-
competitive alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor
antagonist. This is a previously untargeted
post-synaptic glutamate receptor. It is
responsible for mediating rapid trans-synaptic
signal transduction and hence believed to play a
major role in seizure propagation. The three
pivotal placebo-controlled trials of adjunctive
perampanel demonstrated that the effective
dosing range is 4–12 mg/day. The drug can be
prescribed once daily, and its adverse effect
profile is minimal with dizziness, fatigue,
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headache, and somnolence being the most
commonly reported.
Conclusions: Perampanel is a welcome
addition as it represents an alternative
approach in the management of epilepsy with
potential to have a significant impact on the
prognosis of intractable epilepsy. However, it
has only recently been licensed for clinical use
in Europe, the USA, and Canada, and there are
no data directly comparing it with other AEDs;
hence, it remains far too early to ascertain its
place in the treatment of patients with partial
epilepsy.
Keywords: Adjunct therapy; AMPA receptor;
First-in-class; Glutamate; Neurology; Non-
competitive AMPA receptor antagonist; Partial
epilepsy; Perampanel; Refractory epilepsy
INTRODUCTION
Since 1989 there has been an exponential
increase in the number of antiepileptic drugs
(AEDs) used to treat patients with epilepsy, in
general, and those with partial epilepsy in
particular. In addition to the five first-
generation AEDs (carbamazepine,
phenobarbital, phenytoin, primidone, and
valproate), there are ten second-generation
AEDs (felbamate, gabapentin, lamotrigine,
levetiracetam, oxcarbazepine, pregabalin,
tiagabine, topiramate, vigabatrin, and
zonisamide) and four third-generation AEDs
(eslicarbazepine acetate, lacosamide, retigabine,
and perampanel). In addition, there are two
orphan AEDs (rufinamide and stiripentol),
which are licensed for the treatment of specific
‘difficult to treat’ epilepsy syndromes.
Despite the hype, new AEDs have so far had
minimal impact on the prognosis of intractable
partial epilepsy in adults. Thus, whilst 63% of
patients achieved seizure freedom in a cohort of
patients with newly diagnosed epilepsy in 2000
[1], only 5% more achieved seizure freedom
12 years later, despite the introduction of many
new AEDs [2]. These new AEDs, however, are
associated with improved adverse effect profiles
and pharmacokinetic characteristics,
particularly a reduced propensity to
pharmacokinetic interactions, compared with
early AEDs [3].
Recently a new AED, perampanel with a first-
in-class mechanism of action, was approved in
Europe, the USA, and Canada as adjunctive
treatment of partial seizures with or without
secondarily generalization in patients 12 years
and older. The purposes of this review were to
highlight the current management of partial
epilepsy, to analyze the published clinical and
preclinical data of perampanel, and to discuss
its potential place in the treatment of partial
epilepsy.
METHODS
Literature searches of Embase (from 1980 to
April 2013), Medline (from 1950 to April 2013)
and PubMed (from 1966 to April 2013)
databases were conducted in April 2013. The
search terms ‘perampanel’ and ‘AMPA receptor
antagonist/blocker’ were used. Inclusion criteria
included publications written in English,
clinical, and preclinical studies/reviews that
discussed the effects of perampanel or alpha-
amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor
antagonists in epilepsy, or in vitro/in vivo
models of epilepsy. The above search terms
identified 3,186 abstracts. Eighty-nine
publications were selected on the basis of
meeting the above inclusion criteria. Primary
sources were preferred, but review articles were
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used in the absence of a primary reference. Data
contained in summary of product
characteristics (SPCs) were used whenever a
published article was not available.
DISCUSSION
Partial epilepsy
Functionally seizures are divided into partial
and generalized subtypes. Partial, or focal-onset
seizures as they are also known, are thought to
originate in a network of connections that
facilitate seizure propagation constrained to
one cerebral hemisphere [4]. This contrasts
with the concept of generalized seizures,
which are believed to rapidly engage a
network involving both hemispheres [4].
Partial seizures may be simple seizures
involving one area in a hemisphere, for
example an isolated motor seizure, or can be
more complex; there may be alternative
networks of propagation through the
hemisphere or networks that cross to involve
both hemispheres giving rise to secondary
generalized seizures.
Partial epilepsy is a diverse category. This is
reflected by prevalence estimates, which vary
markedly depending on the study population.
Twenty-five separate studies have looked at the
relative prevalence of partial and generalized
epilepsy [5]. In Europe, partial epilepsy accounts
for between 18% and 63% [6, 7] of cases, and in
North America the figure varies from between
12% and 59% [8, 9]. The large variation in these
figures is thought to reflect differences in partial
epilepsy classification and study design between
publications.
Current Management of Partial Epilepsy
A wide range of AEDs with differing
mechanisms of actions are licensed for the
treatment of partial epilepsy. The International
League Against Epilepsy (ILAE) published an
evidence review in 2013 highlighting 13 AEDs,
which have been shown to have varying degrees
of effectiveness as initial monotherapy [10]
(Table 1).
The difficulty arises in establishing which
AEDs should be used first, and in what order
should therapeutic trials progress if initial
monotherapy fails. In patients with refractory
epilepsy, the issue then arises as to which AEDs
are effective as an adjunct. One large health
technology assessment carried out in 2006
concluded that there was little evidence to
support the use of newer AEDs over older
Table 1 AEDs that have been shown to be effective in the ﬁrst-line management of partial epilepsy [10]
Level of evidence Degree of effectiveness
in partial epilepsy
AED
A ‘Established’ Carbamazepine, levetiracetam, phenytoin,
and zonisamide
B ‘Probable’ Valproate
C ‘Possible’ Gabapentin, lamotrigine, oxcarbazepine, phenobarbital,
topiramate, and vigabatrin
D ‘Potential’ Clonazepam and primidone
AED antiepileptic drug
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AEDs as monotherapy or adjuncts [11]. The
assessment was unable to demonstrate
consistently significant differences in AEDs
with regard to efficacy or tolerability.
First-Line AEDs for Partial Epilepsy
In order to answer the question: ‘what is the
best first line AED in partial epilepsy?’, the
‘standard and new antiepileptic drugs study’
(SANAD) was devised [12]. This was a large,
unblinded, randomized controlled trial based in
the UK. It recruited 1,721 patients and
randomized them to receive carbamazepine,
gabapentin, lamotrigine, oxcarbazepine, or
topiramate. With regard to time to treatment
failure, lamotrigine was significantly better than
all alternative AEDs, with the exception of
oxcarbazepine. In addition, carbamazepine was
significantly better than alternative AEDs with
regard to the proportion of patients
experiencing remission at 12 months,
although the advantage was non-significant
when compared with lamotrigine. The authors
concluded that although carbamazepine may be
the more effective drug at maintaining seizure
control, lamotrigine was clinically superior as it
demonstrated better tolerability. The SANAD
study is disputed by some researchers, but for
many experts carbamazepine and lamotrigine
are now considered first-line agents in the
treatment of partial epilepsy.
If the first-line agent fails, then typically
clinicians try a further two AEDs as
monotherapy. AED choice is guided by
multiple factors: (1) the implications of an
AEDs’ known adverse effect profile on patients,
e.g., avoidance of strongly teratogenic agents in
young women, (2) whether an AED has proven
to be effective in specific target groups, e.g., the
elderly or children, groups which have thus far
undergone less investigation than middle-aged
adults, (3) pharmacokinetic characteristics and
drug–drug interaction profile, (4) a clinicians’
experience of individual AEDs, and (5) the cost
of AEDs.
Refractory Partial Epilepsy
In the past, the definition of refractory or drug-
resistant epilepsy varied widely in the academic
literature. Only in 2010 did the ILAE propose a
consensus statement defining drug-resistant
epilepsy as ‘failure of adequate trials of two
tolerated and appropriately chosen and used
AED schedules (whether as monotherapies or in
combination) to achieve sustained seizure
freedom’ [13]. A long-term follow-up study of
1,098 patients, who initially started treatment
in Scotland, identified that failure of seizure
freedom despite multiple AEDs occurs in up to
30% of patients with epilepsy [2]. Of the total
study population, 49.5% of patients became
seizure-free on their first AED, a further 13.3%
on their second, 3.7% on their third, and
successively smaller amounts when subsequent
AEDs were trialed either as monotherapy or
adjunct.
The typical pathway if monotherapy fails is
to continue the AED that has proven most
successful and add an adjunct. Cochrane
reviews have demonstrated that clobazam [14],
eslicarbazepine acetate [15], gabapentin [16],
lamotrigine [17], levetiracetam [18],
oxcarbazepine [19], tiagabine [20], topiramate
[21], vigabatrin [22], and zonisamide [23] are all
effective as adjunctive treatment of refractory
partial seizures. However, there is little guidance
from published literature as to what order these
agents should be trialed, but many look to
combinations with different mechanisms of
action. What is known is that the actual
placebo-corrected efficacy for AEDs as adjuncts
is small [24, 25]. A large meta-analysis
16 Neurol Ther (2013) 2:13–24
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incorporated the results of 54 studies, involving
11,106 patients [25], and demonstrated that,
after correction for placebo, AEDs used as an
adjunct in refractory epilepsy resulted in seizure
freedom in only 6%, and reduced seizure
frequency by more than 50% in only 21% of
patients.
In patients with epilepsy who have failed to
respond to pharmacologic treatment surgery
can be considered. Only a minority of patients
are suitable. Surgery may range from a
minimally invasive procedure, for example,
insertion of a vagal nerve stimulator, to
invasive intracranial surgery. The success rate
varies depending upon the procedure: 66% of
patients with temporal lobe resections will
become seizure-free long term, whilst for
subpial transections, the likelihood of seizure
freedom is only 16% [26].
Perampanel
Mechanism of Action
The pathophysiology of seizure generation
remains poorly understood. Essentially, a
seizure represents an imbalance between
neuronal excitation and inhibition. Synaptic
concentrations of excitatory neurotransmitters
such as glutamate rise, whilst inhibitory
neurotransmitters such as gamma-
aminobutyric acid (GABA) fall [27].
Continuing with this simplification, current
AEDs can be broadly divided into two groups:
agents that act to inhibit excitatory
mechanisms and those that act to promote
inhibitory mechanisms [27] (in reality, many
AEDs have been demonstrated to have multiple
potential mechanisms of action).
Many AEDs including phenobarbital,
tiagabine, topiramate, valproate, and
vigabatrin have been demonstrated to act, at
least in part, by promotion of the inhibitory
GABA pathway. In contrast, the excitatory
pathway is thought to be inhibited at multiple
different points by different AEDs. Two of the
most commonly used AEDs in partial epilepsy
act in this fashion, carbamazepine [28] and
lamotrigine [29]. Their main antiepileptic
activity arises from inhibition of sodium
channels, which act to maintain neuronal
membrane stability.
Targeting Glutamate Pathways
A more direct approach to blocking the
glutamate pathway has been the subject of
much research. Glutamate has a number of
ionotropic and metabotropic receptors. The N-
methyl-D-aspartate (NMDA) and AMPA
receptors are the most extensively explored
within the context of epilepsy. NMDA
receptors were the first target. However, initial
results suggested limited antiepileptic activity,
with epilepsy actually deteriorating in some
patients [30]. In addition, the adverse effect
profile was severe, with a significant proportion
of patients developing frank psychosis.
Perampanel is the first licensed AED to act at
AMPA receptors. It is a non-competitive
antagonist as a result of binding to AMPA
receptors at an allosteric site. This potentially
accounts for part of its therapeutic action.
Initial studies in rat seizure models compared
NBQX and GYKI 52466, respectively,
competitive and non-competitive antagonists
at AMPA receptors [31]. Both were protective in
several seizure models, but in models involving
AMPA-induced seizures, the non-competitive
inhibitor was effective, whereas the
competitive inhibitor was not. Competitive
antagonism to AMPA receptors means that at
high glutamate concentrations, the antagonist
can become displaced by glutamate, permitting
channel opening, subsequent post-synaptic
depolarization, and seizure propagation. High
Neurol Ther (2013) 2:13–24 17
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glutamate concentrations occur during seizures,
meaning that competitive inhibitors are likely
to fail at exactly the point when they are needed
the most. Non-competitive antagonism means
that inhibitory effects are less likely to be
overwhelmed during seizures. Perampanel is a
more soluble, non-competitive successor of
these research agents [32].
In vitro studies have selectively blocked
AMPA and NMDA receptors in neural tissues.
NMDA receptor blockade has little effect on
epileptiform discharge in fully kindled seizures,
although it may shorten the discharge burst [33].
In contrast, selective AMPA receptor blockers
have a marked inhibitory effect on epileptiform
discharge, even in fully kindled seizure models.
AMPA receptors permit sodium, potassium, and
rarely calcium conductance, and are thought to
be the means of rapid glutamatergic signal
transduction [34]. NMDA receptors are blocked
by magnesium at resting membrane potentials
and require significant, sustained depolarization
as provided by high frequency AMPA activity
before they are activated [35]. They allow
conductance of calcium as well as sodium and
potassium. Calcium acts as a potent mediator of
intracellular signal transduction. It initiates a
chain of events responsible for long-term
potentiation (LTP) [34, 35]. Disruption to LTP
pathways is the proposed mechanism for the
development of psychotic symptoms following
human exposure to NMDA receptor antagonists.
In contrast, AMPA receptor antagonists have less
influence on LTP. They are proposed to
mediate routine inter-neuronal synaptic
communication, whilst NMDA receptors are
responsible for longer term synaptic plasticity
[34].
Clinical Trial Data
Perampanel has been studied within the
context of two phase II clinical trials (Studies:
206 and 208) [36], three phase III clinical trials
(Studies: 304, 305 and 306) [37–39] and two
extension studies looking at long-term efficacy
(Studies: 207 and 307) [40, 41].
Efficacy
Three phase III clinical trials assessed the
efficacy of perampanel versus placebo across
doses of 2–12 mg/day. The studies were large,
multicenter, multinational, double-blind
randomized controlled trials that used
intention to treat analysis. The majority of
patients studied were young (mean ages varied
from 33.4 to 36.7 years between the three
studies; all patients were 12 years or older),
Caucasian (61–86%), had on average been
diagnosed with epilepsy for *20 years, and
were considered refractory (average seizures
9–14/28 days, 70% secondarily generalized
seizures). Patients had diagnoses of simple or
complex partial seizures, with or without
secondary generalization. More than 80% of
patients had failed two or more AEDs in the
previous 2 years and were on 1–3 concomitant
AEDs (the most common of which were
carbamazepine, lamotrigine, levetiracetam,
and valproate). For trial inclusion, all
participants had to have at least five partial
seizures during the 6-week baseline period. The
primary endpoints were the responder rate,
defined as the percentage of patients
exhibiting a C50% reduction in seizure
activity, and the percentage change in seizure
frequency. The main secondary endpoints were
the median percentage change in seizure
frequency over 28 days and seizure freedom.
All studies demonstrated a significant
improvement in median change in seizure
frequency with 4–12 mg/day perampanel.
However, only two studies (305, 306) [38, 39]
showed a significant improvement in responder
rate versus placebo (Table 2). A dose-dependent
18 Neurol Ther (2013) 2:13–24
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increment in responder rate and a median
percentage change in seizure frequency were
seen over 4–8 mg/day doses. Doses of 2 mg/day
had no significant effect compared with placebo
[39]. Compared with 8 mg/day doses, 12 mg/day
had no increased effect in responder rates [37,
38] and showed an improvement in median
percentage seizure frequency rates in only one of
the two studies (305) that investigated
perampanel at this higher dose [38]. Study 304,
in which 12 mg/day perampanel failed to make a
difference in median percentage seizure
frequency, also failed to show a change in
responder rate at any dose compared with
placebo.
Several explanations have been suggested for
the lack of significant change in responder rate
with perampanel in Study 304. French and
colleagues proposed that the lack of impact
may be due to: (1) the fact that the responder
rate has a lower sensitivity when compared with
median change in seizure frequency rendering
significant differences harder to establish, or (2)
the findings of Study 304 may have been skewed
by its inclusion of Central and South American
patients, who had a substantially higher placebo
responder rate than the North American
population, with some speculation as to
whether the diagnosis of epilepsy was correct
for some of these patients and if socio-economic
factors played a part in the high placebo
response [39]. Further analysis suggested that if
one looked at just the North American group,
then the responder rate at 8 and 12 mg/day of
perampanel differed significantly from placebo.
This suggests problems with the
implementation of the study in Central and
South America. There do not appear to be any
substantial differences in patient selection. In
both studies 304 and 305, the proportion of
patients with partial and complex partial
seizures, the number of concomitant AEDs at
baseline, baseline seizure frequency, and median
time since diagnosis of epilepsy were similar.
The only difference was that a higher proportion
of patients in 305 were taking levetiracetam
(*38% in Study 305 versus*26% in Study 304).
Thus, the potential for pharmacodynamic
interactions between perampanel and
alternative AEDs cannot be excluded.
An interim report from Study 307: a long-
term, open-label extension of studies 304, 305
Table 2 The clinical effectiveness of perampanel versus placebo in published clinical trials
Perampanel
dose (mg)
Study Patients with ‡50%
reduction in seizure activity
Median change in seizure




2 306 20.6% vs. 17.9% -13.6% vs. -10.7% 6.7% vs. 3.8%
4 306 28.5% vs. 17.9%* p = 0.0132 -23.3% vs. -10.7%* p = 0.0026 2.9% vs. 3.8%
8 304 37.6% vs. 26.4% p = 0.0760 -26.3% vs. -21%* p = 0.0261 9% vs. 8%
305 33.3% vs. 14.7%* p = 0.002 -30.5% vs. -9.7%* p\0.001 9.3% vs. 4.4%
306 34.9% vs. 17.9%* p = 0.0003 -30.8% vs. -10.7%* p\0.0001 7.1% vs. 3.8%
12 304 36.1% vs. 26.4% p = 0.0914 -34.5% vs. -21%* p = 0.0158 26% vs. 8%
305 33.9% vs. 14.7%* p\0.001 -17.6% vs. -9.7%* p = 0.011 19% vs. 4.4%
Data taken from studies 304–306 [37–39]
TRAEs Treatment-related adverse events
* Statistically signiﬁcant; p value\0.05 compared with placebo
Neurol Ther (2013) 2:13–24 19
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and 306, demonstrated that the reduction in
seizure frequency with perampanel was
sustained long term (median duration of
perampanel therapy of 51.4 weeks) [41].
However, the lack of placebo and no
limitation on any additional AEDs added after
the completion of the original phase III studies
render this study difficult to interpret with
regard to long-term efficacy.
Treatment-Related Adverse Events Dis-
continuation from perampanel phase III
clinical trials occurred in 6–19% of patients as
a result of treatment-related adverse events
(TRAEs). These events were dose dependent
(Table 2). The majority of TRAEs were
classified as mild–moderate with very few
studies identifying severe events. The most
common TRAEs in all trials, including
extension studies, were dizziness, fatigue,
headache, and somnolence [37–41]. The
former three events in particular occurred in a
dose-dependent fashion. The adverse events
that most frequently resulted in cessation of
perampanel or dose-reduction were ataxia,
dizziness, convulsion, fatigue, headache, and
vertigo [37–39]. None of the studies
demonstrated a significant worsening of
seizures compared with placebo, and only one
case of sudden unexpected death in epilepsy
occurred [42]. There were no deaths directly
related to perampanel treatment. Weight
increases of up to *2 kg were experienced
with the highest doses of perampanel.
Psychiatric Adverse Events The most
commonly reported behavioral TRAE was
aggression. This increased in a dose-dependent
fashion with 12 mg/day doses resulting in
aggression in up to 3.1% of patients, but
resulting in cessation of therapy in only one
case [42]. Although the data set is small,
aggression appeared to be more common in
adolescents (n = 22, 18.2%) than in the overall
population (n = 53, 4.5%). Three adolescent
patients (2.5%) and 13 adult patients (1.1%)
withdrew due to aggression. Aggression was
severe in 3 adolescents (2.5%) compared with 8
patients in the overall population (\1%).
Reported adverse events were low and similar
to placebo with regard to suicidality and other
behavioral disorders. These tended to occur in
patients with a strong personal history of
mental health disorder and other potentially
precipitating factors were normally identified,
for example, recent cessation of risperidone in
one patient.
Pharmacokinetic Profile Perampanel displays
good oral bioavailability (100%), is rapidly
absorbed (Tmax, 0.25–2.0 h) and demonstrates
no sign of significant first-pass metabolism. It
is *95% plasma protein bound and is widely
distributed throughout tissues with a volume
of distribution of 1.1 L/kg. Perampanel
demonstrates linear pharmacokinetics in
healthy individuals at doses of 2–12 mg/day.
It is extensively metabolized (98%) primarily
by CYP3A4 (although CYP3A5 may also
contribute)-mediated oxidation and then
undergoes sequential glucuronidation to
produce various glucuronide conjugates. In
the absence of CYP3A inducers, the half-life
of perampanel in adult healthy volunteers is
51–129 h (mean 105 h) after single dose and
66–90 h after multiple-dose administration
[43, 44]; this can be reduced to *25 h with
strong enzyme inducers, e.g., carbamazepine.
Seventy percentage of a perampanel dose is
excreted in feces, the rest by the renal system
[45]. Only *2% of an administered dose is
excreted as unchanged perampanel in urine.
The usual dosage of perampanel is 4–12 mg/
day.
20 Neurol Ther (2013) 2:13–24
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The pharmacokinetics of perampanel has
important implications for its use. Its long
half-life means that perampanel can be
prescribed once daily, which will enhance
patient compliance. Caution should be taken
in the context of concomitant CYP3A4 inducers
including AEDs such as carbamazepine,
oxcarbazepine, phenytoin, and topiramate,
and non-AEDs such as rifampicin (although no
data on an effect of rifampicin are available) as
they may significantly reduce circulating levels
of perampanel (area under the curve [AUC]
values are decreased by a mean 20–67%),
thereby reducing the responder rate. Similarly,
the CYP3A inhibitor ketoconazole has been
shown to elevate the mean plasma perampanel
AUC values by 20%. In contrast, perampanel
had little impact on other AEDs, with the
exception of oxcarbazepine where it increased,
via an unknown mechanism, circulating plasma
levels by 35%. The clinical significance of this
interaction is unknown because the
pharmacologically active metabolite of
oxcarbazepine, 10-hydroxycarbazepine, was
not measured. In addition, perampanel is both
hepatically and renally excreted; hence, caution
should be taken in patients with hepatic and
renal impairment.
Perampanel’s Potential in Management
Pathways Perampanel has only been studied
in humans within the context of refractory
partial epilepsy in clinical trials of highly
selected patients. Rat models of absence
epilepsy have shown perampanel to be
ineffective in this condition [46]. Published
data regarding the effectiveness of perampanel
in primary generalized epilepsies and as
monotherapy for partial epilepsy are not
available; thus, it is unclear how effective it
could be in these settings. Post-hoc analyses of
the original phase III clinical trials have shown
that perampanel is significantly effective in the
management of partial onset seizures with
secondary generalization [47]. This is
important as these patients are harder to
manage than those with simple partial
seizures. Perampanel demonstrated a clinically
significant, dose-dependent rise in responder
rate and median change in secondary
generalized seizure activity at doses up to
8 mg/day. This has been demonstrated for
many older AEDs: carbamazepine [48],
lacosamide [49], lamotrigine [50],
levetiracetam [51], phenytoin [48], topiramate
[52], and valproate [48], but little published
data are available with respect to the ability of
alternative newer AEDs in this context.
Perampanel’s application in the
management of pediatric epilepsy has yet to
be established. The original trials contained
small numbers of adolescents aged [12 years.
Aside from a suggested increase in the risk of
behavioral side effects in adolescent compared
with adult patients [42], little information with
regard to relative efficacy and rates of other
TRAEs is known.
CONCLUSIONS
During the last two decades, 14 AEDs have been
specifically licensed for the treatment of
intractable partial epilepsy but with little
impact on the prognosis of such patients
overall, although for some individual patients
seizure freedom has been achieved. An ongoing
observational study by Brodie and colleagues
has looked at the number of patients who go on
to become seizure-free following their initial
diagnosis of epilepsy. The group has published a
series of follow-up analyses over the course of a
decade. In the first study published in 2000,
63% of patients ultimately became seizure-free
[1], in the latest study published in 2012 this
Neurol Ther (2013) 2:13–24 21
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figure was 68% [2]. That is a disappointing
increment of only 5% over 12 years, in spite of
the introduction of these new AEDs.
Intractable partial epilepsy is an epilepsy
subtype crying out for ground-breaking new
drugs. Perampanel’s novel mechanism of action
as a non-competitive AMPA receptor antagonist
represents a new and previously unexplored
target. Furthermore, its non-competitive
antagonism means that at high glutamate
concentrations, perampanel’s inhibitory effects
are less likely to fail and consequently it may be
particularly useful in refractory patients. In
addition, clinical trials have demonstrated that
perampanel is effective in refractory partial
epilepsy and that it has a relatively mild
adverse effect profile.
There is, however, as yet no trial data
comparing perampanel with alternative AEDs.
The difficulty for clinicians remains how to pick
one adjunct over another. As perampanel has
only recently been licensed for clinical use, and
since there are no data directly comparing
perampanel with other AEDs, it remains far
too early to ascertain the place of perampanel in
the treatment of patients with epilepsy.
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